

Pioneering the Future of Global Cannabis

November 2019

©2019 TILRAY

Disclaimer

Investors and prospective investors should rely only on the information contained in the continuous disclosure filings (the "Filings") of Tilray Inc. (the "Company"). This presentation is qualified in its entirety by reference to, and must be read in conjunction with, the information contained in the Filings. An investor or prospective investor is not entitled to rely on parts of the information contained in the ispesentation to the exclusion of others, and the Company is not authorized to provide different or additional information. Unless otherwise specified, all monetary amounts in this presentation are in United States dollars.

An investment in the securities discussed in this presentation is speculative and subject to a number of risks that should be considered by an investor or prospective investor. Investors and prospective investors should carefully consider the risks described in the Filings. This presentation does not constitute an offering of securities and the information contained herein is subject to the information contained in the Company's Filings.

FORWARD-LOOKING INFORMATION

This presentation contains "forward-looking information" within the meaning of applicable securities laws in Canada or "forward-looking statements" made pursuant to the "safe harbour" provisions of the United States Private Securities Litigation Reform Act of 1995 (collective), "forward-looking information"). Forward-looking information may relate to the Company's biture outlook and anticipated events, plans or results, and may include information regarding the Company's objectives, goals, strategies, future revenue or performance and capital expenditures, and other information that is not historical information. Particularly, information regarding the Company's expectations of performance, achievements, prospects or opportunities, or the markets in which the Company operates, is forwardlooking information. Forward-looking information can often be identified by the use of terminology such as "believe", "anticipate," "plan," "expect," "pending," "in process," "intend," "estimate," "project," "may," "will," "should," "would," "could," "can," the negatives thereof, variations thereon and similar expressions. In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances contain forward-looking information. Settements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events or circumstances.

The forward-looking information contained in this presentation is based on the Company's opinions, estimates and assumptions in light of management's experience and perception of historical trends, current conditions and expected future developments, as well as other factors that management currently believes are appropriate and reasonable in the circumstances. Despite a careful process to prepare and review the forward-looking information, there can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct.

Risk factors that could cause actual results to differ materially from forward-looking information in this presentation include: the Company's ability to secure and maintain required regulatory approvals and licenses to manufacture and export medical cannabis and other products derived therefrom; risks relating to evolving laws, regulations and guidelines applicable to medical cannabis in Canada and other countries further limiting the Company's the busi operations; the Company's failure to comply with applicable regulations in any jurisdiction resulting in a significant change in business operations: the Company's continued ability to export medicinal cannabis is dependent upon The second approvals outside of Canada and any failure to comply may limit the Company's international expansion; the effect of the legalization of adult-use cannabis in Canada on the medical cannabis industry is unknown and may significantly and negatively affect the Company's medical cannabis business; that the medical benefits, viability safety, efficacy, dosing and social acceptance of cannabis are not as currently expected; that adverse changes or developments affecting the Company's main or planned facilities may have an adverse effect on the Company; that the medical cannabis industry and market may not continue to exist or develop as anticipated or the Company may not be able to succeed in this market; risks related to market competition; risks related to the adult-use can industry and market in Canada including the Company's ability to enter into or compete in such market; risks re to adult-use regulations in Canada developing in a manner from current expectations, including new Canadian adult regulations effective December 17, 2019, that the Company fails to comply with supplier standards established Canadian provincial or territorial distributors; that the Canadian adult-use cannabis market experiences continued supply fluctuations resulting in revenue and price declines; the nascent Canadian adult-use market being subject to many of the same regulatory and early-stage growth risks as medical cannabis; enhanced legal competition for Canadian adult-use market share; that the Company has a limited operating history and a history of net losses and that it may not achieve or maintain profitability in the future: risks related to the Company's current or proposed international operations; risks related to the orgoing development and enforcement of U.S. and foreign laws, including recent U.S. legalization of hemp-derived CBD products and the Company's ability to successfully

arcialize such products; risks related to future third party strategic alliances or the expansion of currently con existing relationships with third parties; that the Company may not be able to successfully identify and execute future acquisitions or dispositions or successfully manage the impacts of such transactions on its operations; risks inherent to the operation of an agricultural business; that certain customer concentrations constitute a substantial sortion of the Company's revenues; that the Company may be unable to attract, develop and retain key personnel; isks resulting from significant interruptions to the Company's access to certain key inputs such as raw materials, electricity, water and other utilities; that the Company may be unable to transport its cannabis products to patients in a safe and efficient manner; risks related to recalls of the Company's cannabis products or product liability or regulatory claims or actions involving the Company's cannabis products; risks related to the Company's reliance on pharmaceutical distributors; that the Company, or the cannabis industry more generally, may receive unfavorable sublicity or become subject to negative consumer or investor perception; that certain events or developments in he cannabis industry more generally may impact the Company's reputation or its relationships with customers or suppliers; that Canadian product licensure and marketing regulations further constrain the Company in promoting its products; risks related to the Company's ability to comply with all safety, health and environmental regulations applicable to it; that the Company may not be able to obtain adequate insurance coverage in respect of the risks that it faces, that the premiums for such insurance may not continue to be commercially justifiable or that there may be coverage limitations and other exclusions which may result in such insurance not being sufficient; that the Company may become subject to liability arising from fraudulent or illegal activity by its employees, contractors, consultants and others; that the Company may experience breaches of security at its facilities or losses as a result of the theft of its products; risks related to the Company's information technology systems; that the Company may be un to sustain its revenue growth and development; that the Company may be unable to expand its operations quickly enough to meet demand or manage its operations beyond their current scale; that the Company may be unable to secure adequate or reliable sources of necessary funding: that the Company may not generate sufficient cash flow to service its debt obligations and fund our ordinary course business operations; risks related to, or associated with, the Company's exposure to public company reporting requirements; risks related to conflicts of interest; risks related to third-parties' perceived reputational risk of engaging in the cannabis industry and with the Company; risks related to unforeseen changes in tax and accounting requirements; risks related to fluctuations in foreign currency exchange rates; risks related to the Company's potential exposure to greater than-anticipated tax liabilities and long term effects of U.S. tax reform; risks relating to a permanent U.S. ban on entry for non-U.S. citizens who admit to cannabis investing or employment; risks related to the protection and enforcement of the Company's intellectua property rights, or the intellectual property that it licenses from others; that the Company may become subject to allegations that it or its licensors are in violation of the intellectual property rights of third parties; that the Company may not realize the full benefit of the clinical trials or studies that it participates in; that the Company may not realize the full benefit of its licenses if the licensed material has less market appeal than expected and the licenses

may not be profitable; risks related to our pending merger with Privateer Holdings, lnc's and it and Privateer's founders controlling ownership in the Company, its provision of services to the Company and its participation in the Company's management and as well as any other risks that may be included in the films. Please see the heading "Risk Factors" in Tilray's most recent Quarterly or Annual Report on Form 10-Q or Form 10-K, which are filed with the Securities and Exchange Commission and Canadian securities regulators, for a discussion of the material risk factors that could cause actual results to differ materially from the forward-looking information.

Although management has attempted to identify important risk factors that could cause actual results to differ materially from those contained in the forward-looking information in this presentation, there may be other risk factors not presently known to the Company or that the Company presently believes are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information in this presentation. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers and viewers should not place undue reliance on forward-looking information, which speaks only as of the date made. The forwardlooking information contained in this presentation represents the Company's expectations as of the date of this presentation or the date indicated, regardless of the time of delivery of the presentation. The Company disclaims any intention, obligation or undertaking to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required under applicable securities laws.

All of the forward-looking information contained in this presentation is expressly qualified by the foregoing cautionary statements. Investors and potential investors should consult their own professional advisors to ascertain and assess

the income tax, legal, risk fa should carefully consider th

In connection with the prc has filed a registration stat information statement of Pi proxy statement/prospec information about Tilray, I other relevant materials (wi be obtained free of charge obtain free copies of the d Maughan Road, Nanaimo, E to read the proxy statemer available before making any

This communication shall n offer to buy any securities, I or sale would be unlawful p offering of securities shall I the Securities Act.

PARTICIPANTS IN THE SC

Tilray and its directors and e to be participants in the sitransaction. Information reare included in the proxy siregarding the directors and connection with its 2019 A are available free of charge address above.

USE OF NON-U.S. GAAP

To supplement its financia EBITDA, which is not a fint in the United States ("U.S. net; other income, net; de net; depreciation and amor expenses. A reconciliation been provided in the finar November 13, 2019. The C investors regarding certain operations. Management 1

for trend analyses and plan

The information contained independently verified and be placed on, the fairness,

We Are a Global Pioneer in a \$150B¹+ Marl

We were the first cannabis company to:

Receive cultivation licenses from mu

Achieve GMP certification

Export cannabis legally from North A Africa, Australia, Europe and Latin Ar

Supply federally approved clinical tria Australia, Canada and the United Sta

Recruit majority women Board of Di

Complete an IPO on a major U.S. sto

SOURCE: UNITED NATIONS WORLD DRUG REPORT. PROJECTIONS INCLUDE THE ILLICIT MARKET

Mission

Improve patients' and consumers' lives through the power of cannabis and hemp

Brands Matter

We are building a multi-billion dollar global consumer packaged goods company with a portfolio of medical, wellness and adult-use brands consumers love

Committed to Creati Shareholder Value B

Growing revenue and market sh

Focusing on the biggest, long-te

Investing aggressively now, for s and profitable growth over the lo

Attracting and rewarding long-te capital, including significant insid

We Are a Trusted Partner Legitimizing Ca

10 Clinical Trials





SickKids UC San Diego


COLUMBIA UNIVERSITY 50

MEDICAL CENTER

Medical Advisory Board



Orrin Devinsky, MD, Chairman



Chachoua, MD



Catherine Lord, PhD



Hale, MD

3 Strategic Partnerships

ABInBev SA ABG BR

International Advisory Boa













Llovd Ax

Gosse Downer

Donald McKin

James O'Brie

We Are Building a Global Platform for the



¹ SEE DISCLAIMER: FORWARD-LOOKING INFORMATION ² PENDING REGULATORY APPROVAL ³ FACILITY UNDER CONSTRUCTION

³ FACILITY UNDER CONSTRUCTION

Team of Industry Experts



Brendan Kennedy President & Chief Executive Officer





Mark Castaneda Chief Financial Officer

PRIMO DRINK BIG. DRINK HEALTHY.



Woody Pastorius Chief Revenue Officer

THOMSON REUTERS



Adine Carter Chief Marketing Officer

ANDREW PELLER



Dara Redler General Counsel

Coca:Cola



Rita Seguin Executive Vice President, Human Resources

DIAGEO



Greg Christopher Executive Vice President, Operations

Nestlé



Kristina Adamski Executive Vice President, Corporate Affairs





Catherine Jacobson, PhD Vice President, Regulatory & Medical Affairs

GNV phermaceuticals



Charlie

Strategic, Global Production Footprint

Our total production area is 3.4 million square feet as of November 2019

	Д	ILRAY		hemp		
	CANADA NANAIMO, B.C.	PORTUGAL cantanhede / esporão	FARMS ENNISKILLEN, ON	PROCESSING	GARDENS LEAMINGTON, ON	WINNIPEG, MB
PARCEL SIZE	218K SQFT	11.5M SQFT	4.4M SQFT	215K SQFT	784K SQFT	38K SQFT
PHASE I Development	60KSQFT COMPLETE	2.7M SQFT	626K SQFT	56K SQFT	155K SQFT	15K SQFT
MAX Development	80K SQFT	10.2M SQFT	3.5M SQFT	122K SQFT	660K SQFT	
CULTIVATION FORMAT	INDOOR	INDOOR/ GREENHOUSE/ OUTDOOR	GREENHOUSE/ OUTDOOR		GREENHOUSE	

Portfolio of Appealing Products Supporte by Extensive Distribution Capabilities

Broad Array of Products to Address Consumer Needs

Available Online and in the USA and 3,600 Sto

Hemp Hearts	HEAPTS				
Protein Powder					
Hemp Oil					
Granola & Bars	Coming Soon ⁽¹⁾				
CBD					



PRODUCT PACKAGING NOT FINAL

¹ HEMP FOOD DISTRIBUTION

Portugal is Our International Production Hub

2.5 million square feet

Low costs (climate and labor)

Import raw material from other countries

Export finished goods


Tariff-free access to EU

Capacity to manufacture 3-4x current cultivation output

Strategic alliance with agricultural leader Esporão


Final GMP certifications by end of 2019¹

SEE DISCLAIMER: FORWARD-LOOKING INFORMATION



Well-Positioned for the EU¹

We have established cultivation, distribution agreements, and sales offices in the European Union to capture the €36B^{1,2} European market opportunity



SEE DISCLAIMER: FORWARD LOOKING INFORMATION

² SOURCE: PROHIBITION PARTNERS. PROJECTIONS BASED ON FULLY LEGAL AND REGULATED MARKET IN EUROPE.

³ SOURCE: BASED ON STATISTICS PROVIDED BY THE INTERNATIONAL MONETARY FUND AND UNITED NATIONS

Multiple Paths for Revenue Growth

Global Adult-Use

2 Countries Canada & Uruguay Global Medical

41 Countries

Glol Hen

50+ Cc Includir

Adult-Use

Proven Track Record

Sequentially increased Canadian adult-use revenue $Q1 \rightarrow Q2 \rightarrow Q3$

Coast to coast distribution in Canada

6 brands, more than 50 SKU's

Minority investments in 3 retailers, and definitive agreement to acquire FOUR20 retail business

3 licensed facilities

Processing capacity exceeds cultivation capacity, consistent with long-term vision of supply/demand dynamics



Adult-Use

Future Milestones¹

Introduce new form factors:

- Vapes
- Edibles
- Beverages

Launch additional brands

Launch ABInBev JV products


Launch Fluent CBD beverages in market

Continue research in THC-beverages

Expand production capacity

Expect 3–4 additional countries to legalize by end of 2020

¹ SEE DISCLAIMER: FORWARD-LOOKING INFORMATION



Medical

Proven Track-Record

Products available in 13 countries on 5 continents

12 pharmaceutical distributor relationships, including global agreement with Sandoz

10 clinical trials

GMP certified

Established Medic



Pharmaceutical Pa



Medical

Future Milestones¹

Import raw material from other countries to Portugal

Obtain final GMP certifications in Portugal

Expand product offerings in existing markets

Complete exports from Portugal to additional international markets

Extend pharmaceutical partnerships to additional countries and regions

Supply additional clinical trials





' SEE DISCLAIMER: FORWARD-LOOKING INFORMATION

Hemp/CBD

Proven Track-Record

Hemp Distribution in 20 countries

~17,000 stores in North America

30,000+ acres of hemp under contract

100+ SKU's

CBD Signed revenue sharing agreement with Authentic Brands Group

Launched Manitoba Harvest CBD products in the U.S.

Completed Smith & Sinclair acquisition

Achieved GRAS for Manitoba Harvest CBD products

Partnership



Products



Retailers

Loblaws	amazon	Weg
WHÔLE FOODS	COSTCO	SPR
♥CVS	FRESHMIHYME	me
Jobey	H·E·B	the St

Hemp/CBD

Future Milestones¹

Launch CBD products with Authentic Brands Group

Launch new CBD brands in the U.S.

Launch Smith & Sinclair CBD products in the U.S.

Launch cannabinoid seed and oil based products in the EU

New products

New markets

Add retailers

SEE DISCLAIMER: FORWARD-LOOKING INFORMATION

CBD Products

NINE WEST

Other Cannabinoi

Cannabinoid	Potential The
CBN	Sleep disorders
тнси	Obesity, PTSD,
CBDV	Epilepsy, Fractu
CBG	Anxiety, Bladde
СВС	Pain IBD, Emesi
CBCV	Epilepsy, Depre
Delta8-THC	Emesis , PTSD

Cannabis—**Disruption is Underway**¹




BOXES INDICATE PARTIES WITH PUBLICLY ANNOUNCED CURRENT INVOLVEMENT OR PARTNERSHIPS IN THE CANNABIS INDUSTRY SEE DISCLAIMER: FORWARD-LOOKING INFORMATION

Cannabis—**Disruption is Underway**¹




BOXES INDICATE PARTIES WITH PUBLICLY ANNOUNCED CURRENT INVOLVEMENT OR PARTNERSHIPS IN THE CANNABIS INDUSTRY ¹ SEE DISCLAIMER: FORWARD-LOOKING INFORMATION

Quarterly Revenue Growth



¹ BASED ON TILRAY'S INTERIM UNAUDITED FINANCIAL STATEMENTS FOR THE QUARTERS ENDED MARCH 31, 2017/2018/2019 THE SIX MONTHS ENDED, JUNE 30, 2017/2018/2019, THE NINE MONTHS ENDED S 2017/2018/2019, AND THE AUDITED FINANCIALS YEARS ENDED DECEMBER 31, 2017/2018.

Historical Financial and Operating Perform



Kilogram Equivalents S



Selling Price vs CO





BASED ON TILRAY'S AUDITED ANNUAL FINANCIAL STATEMENTS FOR THE YEARS ENDED DECEMBER 31, 2016, 2017 AND 2018 AND UNAUDITED STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 20 INCOME STATEMENT FIGURES ARE CONVERTED AT THE SPOT RATE FOR EACH MONTH.

Long-Term Financial Targets¹

	Estimate as a % of
Gross Margin	50%+
Adjusted EBITDA	25%+
Operating Income	20%+

¹ SEE DISCLAIMER: FORWARD LOOKING INFORMATION AND USE OF NON-U.S. GAAP FINANCIAL MEASURES.

Path to Profitability¹

Short-Term

Increase scale, thereby decreasing costs

Expand leadership in higher-margin international medical markets

Launch higher-margin products and form factors such as vapes, edibles, etc.

Leverage Manitoba Harvest infrastructure to launch U.S. CBD


Build brand awareness of portfolio of brands

Long-Term

Increase distribution of high-margin, value-added branded products globally in medical and adult-use markets

Continue R&D to drive product development and improvement in product mix

¹ SEE DISCLAIMER: FORWARD LOOKING INFORMATION



Backed by Long-Term, Patient Capital

Extended Lock-Up Provides for Orderly Release of Largest Stockholders' Shares

Benefits to Tilray

• Enables capital raising & strategic M&A

Shares owned by Privateer per-transaction

- Enables orderly share distribution
- Increases liquidity to attract a
- Post downstream merger, Tilra other co-founders will own 30

Downstream merger of Privateer into Tilray, expected to close by year-end



Lock-up expires over ty

Year One

At Tilray's discretion, marketed offe or block trades to institutional inves or stock sales to strategic investors

Year Two

Remaining shares subject to a stag

¹ REFER TO RULE 425 LEGEND

It's Day One in the Cannabis Industry

\$150B¹+ Opportunity

Early Days in the Beginning of a Global Paradigm Shift

41/196 countries have legalized medical

2/196 countries have legalized adult-use

We Will Win Becaus

Global Pioneers

Brand Builders

The Trusted Partner

Talented Management

Investing Aggressively Now Long-Term Profitability

Backed by Long-Term, Patie

SOURCE: UNITED NATIONS WORLD DRUG REPORT. PROJECTIONS INCLUDE THE ILLICIT MARKET.

Appendix

Financial Performance¹

Consolidated Statement of Net Los	THREE MONTH ENDED MARCH 31,	THRE ENDEI			
	2016	2017	2018	2019	2
Revenue	\$ 12,644	\$ 20,538	\$ 43,130	\$23,038	
Cost of Sales	9,974	9,161	28,855	17,653	
Gross Profit	2,670	11,377	14,275	5,385	
Gross Margin %	21%	55%	33%	23%	
Research and Development Expense	1,136	3,171	4,264	1,048	
Sales and Marketing Expenses	3,599	7,164	15,366	7,821	
General and Administrative Expense	4,890	8,401	31,307	14,659	
Loss from Equity Method Investments	-	-	-	-	
Stock-Based Compensation Expense	94	139	20,988	5,306	
Acquisition-Related (income) Expense, Net	-	-	-	4,424	
Operating Loss	(7,049)	(7,498)	(57,650)	(27,873)	

Tilray Sources of Revenue¹ (USD \$ in thousands)

	YEAR ENDED DECEMBER 31,					
	2016	% of Revenue	2017	% of Revenue	2018	% of Revenue
Dried Cannabis	\$11,324	89.6%	\$16,260	79.2%	\$21,674	50.3%
Cannabis Extracts	1,107	8.8%	3,965	19.3%	21,179	49.1%
Accessories	213	1.7%	313	1.5%	277	0.6%
Hemp Products	-	0.0%	-	0.0%	-	0.0%
Total	12,644	100%	20,538	100%	43,130	100%

¹ BASED ON TILRAY'S AUDITED ANNUAL FINANCIAL STATEMENTS FOR THE YEARS ENDED DECEMBER 31, 2016/2017/2018, AND UNAUDITED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 2019 AND SIX MONTHS ENDED JUNE 30, 2019, AND NINE MONTHS ENDED SEPTEMBER 30, 2019.

Clinical Trial Strategy¹

Build halo around the Tilray brand

Earn credibility with medical community and governments

Build government relationships and enter new markets

Generate data to inform treatment and expand the addressable mark

Create optionality to register or license medicines if they are found to be safe and efficacious

Partner with government and research institutions with existing capital for research expenses

¹ SEE DISCLAIMER: FORWARD-LOOKING INFORMATION

Clinical Trials

Participation in clinical trials furthers our reputation as the most trusted brand in th

Country	Indication	Research Partners	Drug Product	Phase	No. Of Patients ¹	Start Date ¹	Completion Date ¹	IP Owner Clinical Trial Drug
Australia	Chemotherapy-Induced Nausea and Vomiting (CINV)	NSW Government, University of Sydney, Chris O'Brien Lifehouse	Capsule; combination drug product (CBD &THC)	&	Phase II: 80 Phase III: 250	Phase II: Q4 2016 Phase III: Q1 2019	Phase II: Q4 2018 Phase III: Q1 2021	Tilray
Australia	Severe Behavioral Problems in Children with Intellectual Disabilities	Murdoch Children's Research Institute	Oral solution; combined drug product (CBD & THC)	II	10	TBD	TBD	Tilray
Spain	Glioblastoma ²	Grupo Español de Investigación en Neuroocología (GEINO)	Oral solution; combination drug product (CBD & THC)	lb	30	Q3 2018	Q4 2019	Tilray
USA	Essential Tremor	University of California, San Diego (UCSD)	Capsule; combination drug product (CBD & THC)	lla	16	Q1 2019	Q2 2020	Tilray
USA	Alcohol Use Disorder (AUD)	New York University School of Medicine	Capsule; drug product (CBD)	II	40	Q3 2019	Q2 2020	Tilray
USA	Post-Traumatic Stress Disorder (PTSD) with Alcohol Use Disorder	New York University School of Medicine	Capsule; drug product (CBD)	II	60	Q3 2019	Q2 2020	Tilray
USA	Taxane-Induced Peripheral Neuropathy (TIPN)	Columbia University Irving Medical Center (CUIMC)	Capsule; combination drug product (CBD & THC)	I.	TBD	Q4 2019	TBD	Tilray
Canada	HIV/AIDS; Inflammation ²	McGill University	Capsule solution; combined drug product (CBD & THC)	II	26	TBD	TBD	Tilray
Canada	Pediatric Epilepsy	Toronto's Hospital for Sick Children (SickKids)	Oral solution; combination drug product (CBD &THC)	I Open-label	20	Q4 2017	Q1 2018 (complete)	Tilray
Canada	Post-Traumatic Stress Disorder (PTSD)	University of British Columbia	Vaporized dried cannabis	II	42	Q4 2016	Q2 2019	Tilray

¹ SEE DISCLAIMER: FORWARD-LOOKING INFORMATION ² REGULATORY APPROVAL PENDING

Established Medical Brand

We believe patients choose Tilray because we are a scientifically rigorous brand known for producing pure, precise and predictable medical-grade products



Global Medical Opportunity

41 countries have authorized medical use. Our products are in 13 countries.



Australia 8

Completed m

' TILRAY PRODUCTS NOT CURRENTLY AVAILABLE IN THESE COUNTRIES

Global Medical Partnerships

In order to efficiently and rapidly increase our scale, we are partnering with established pharmaceutical distributors and pharmacy retailers



Board of Directors

The first women-led board of a major cannabis company



Brendan Kennedy
Chief Executive Officer





Christine St.Clare

Retired Partner





Rebekah Dopp
Principal





Scotty Greenwood Chief Executive Officer



International Advisory Board

Nine internationally-renowned business and government leaders who advise Tilray



Governor Howard Dean Former DNC Chairman and Governor of Vermont



Michael Steele Former RNC Chair and Lt. Governor of Maryland



Lloyd Axworthy Former Canadian Minister of Foreign Affairs



Joschka Fischer Former German Foreign Minister and Vice Chancellor



Alexander John Gosse Downer Former Australian Foreign Minister



Donald McKinnon Former New Zealand Foreign Minister and Deputy Prime Minister



James O'Brien Former U.S. Special Presidential Envoy



Dr. Lorn Former (

Medical Advisory Board

The Medical Advisory Board participates in our clinical trial selection process and provides Tilray with additional credibility as a clinical trial participant

Highly accomplished researchers and physicians



Orrin Devinsky, MD, Chairman

Director

Comprehensive Epilepsy Center

NYU Langone



Abraham Chachoua, MD

Associate Director

Perlmutter Cancer Center

NYU Langone



Catherine Lord, PhD

Professor and Director

Center for **Autism** and the Developing Brain

Cornell and Columbia Universities